Want to see HK:6622 full AI Analyst Report?
6622 Stock Chart & Stats
HK$3.17
HK$0.01(0.78%)
At close: 4:00 PM EST
HK$3.17
HK$0.01(0.78%)
Day’s Range― - ―
52-Week RangeHK$2.38 - HK$4.60
Previous CloseN/A
Volume310.50K
Average Volume (3M)1.25M
Market Cap
HK$1.50B
Enterprise ValueHK$502.65
Total Cash (Recent Filing)HK$1.30B
Total Debt (Recent Filing)HK$292.48M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding548,749,000
10 Day Avg. Volume1,172,850
30 Day Avg. Volume1,251,992
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)0.92
Price to Sales (P/S)46.69
P/FCF Ratio-5.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)HK$421.50M
Bulls Say, Bears Say
Bulls Say
Focused Ophthalmology FranchiseA focused ophthalmology business model concentrates scientific, regulatory and commercial efforts on a single therapeutic area, enabling deeper expertise and faster product development cycles. Combining in-house R&D with in-licensing diversifies pipeline risk and can speed time-to-market versus pure discovery plays, supporting durable commercial capability if execution holds.
Relatively Supportive Balance SheetModest leverage and a sizable equity base provide the company with financial flexibility to fund ongoing R&D and commercialization in the medium term. This reduces immediate solvency pressure compared with highly leveraged biotech peers and gives management time to execute development and business plans before needing urgent external financing.
Established Commercial Revenue BaseHaving generated commercial revenue indicates the company has moved at least some assets through regulatory and go-to-market processes. Even if volatile, an existing revenue base demonstrates distribution and commercialization capability that can be scaled or leveraged through partnerships and in-licensing, supporting potential recovery and growth if execution improves.
Bears Say
Sustained Cash BurnConsistent and large negative operating and free cash flows imply ongoing funding needs and reduce strategic optionality. Persistent cash burn forces reliance on equity raises or debt, which can dilute shareholders or increase leverage, and constrains the firm's ability to invest in R&D, marketing, or manufacturing over the next several quarters without external financing.
Deep And Persistent Losses; Negative Gross ProfitA sharp revenue decline coupled with negative gross profit indicates current cost structure exceeds sales, undermining margin sustainability. Persistent operating losses mean the company has not demonstrated a scalable, profitable model; this raises execution risk and makes it harder to restore profitability without structural cost reductions or revenue re-acceleration.
Negative Returns On Equity; Equity Erosion RiskSustained negative ROE shows the company is destroying shareholder value and signals that accumulated losses may erode the equity cushion over time. Even with current equity strength, continued negative returns increase the likelihood of dilutive capital raises or material write-downs, impairing long-term investor returns and the firm's ability to finance growth internally.
Zhaoke Ophthalmology Ltd. News
6622 FAQ
What was Zhaoke Ophthalmology Ltd.’s price range in the past 12 months?
Zhaoke Ophthalmology Ltd. lowest stock price was HK$2.38 and its highest was HK$4.60 in the past 12 months.
What is Zhaoke Ophthalmology Ltd.’s market cap?
Zhaoke Ophthalmology Ltd.’s market cap is HK$1.50B.
When is Zhaoke Ophthalmology Ltd.’s upcoming earnings report date?
Zhaoke Ophthalmology Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 40 days.
How were Zhaoke Ophthalmology Ltd.’s earnings last quarter?
Zhaoke Ophthalmology Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.184 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Zhaoke Ophthalmology Ltd. overvalued?
According to Wall Street analysts Zhaoke Ophthalmology Ltd.’s price is currently Overvalued.
Does Zhaoke Ophthalmology Ltd. pay dividends?
Zhaoke Ophthalmology Ltd. does not currently pay dividends.
What is Zhaoke Ophthalmology Ltd.’s EPS estimate?
Zhaoke Ophthalmology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhaoke Ophthalmology Ltd. have?
Zhaoke Ophthalmology Ltd. has 548,749,000 shares outstanding.
What happened to Zhaoke Ophthalmology Ltd.’s price movement after its last earnings report?
Zhaoke Ophthalmology Ltd. reported an EPS of -HK$0.184 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.614%.
Which hedge fund is a major shareholder of Zhaoke Ophthalmology Ltd.?
Currently, no hedge funds are holding shares in HK:6622
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhaoke Ophthalmology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.41%
12-Months-Change
Fundamentals
Return on Equity
-12.64%
Trailing 12-Months
Asset Growth
-9.72%
Trailing 12-Months
Company Description
Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is advancing a range of medications designed for various ocular conditions, impacting both the anterior and posterior segments of the eye, such as dry eye disease, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. It was previously known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was established in 2017 and operates from its headquarters in Guangzhou, People's Republic of China.